Document is current
Any future updates will be listed below
-
Authors
Deng, Jiayin https://orcid.org/0000-0002-6767-4179
Gutiérrez, Lucía G.
Stoll, Gautier https://orcid.org/0000-0002-0862-4139
Motiño, Omar https://orcid.org/0000-0002-3858-0966
Martins, Isabelle
Núñez, Lucía
Bravo-San Pedro, José Manuel
Humeau, Juliette
Bordenave, Chloé
Pan, Juncheng
Fohrer-Ting, Hélène
Souquere, Sylvie
Pierron, Gerard
Hetz, Claudio
Villalobos, Carlos https://orcid.org/0000-0002-0429-3846
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Senovilla, Laura https://orcid.org/0000-0001-6887-2436
-
Funding
Funding for this research was provided by:
Ligue Contre le Cancer
Agence Nationale de la Recherche
Fondation pour la Recherche Médicale
Institut National Du Cancer
Institut Universitaire de France
Fondation Leducq
- License Information
-
More Information
Article History
Received: 8 June 2021
Revised: 28 September 2021
Accepted: 6 October 2021
First Online: 1 November 2021
Competing interests
: GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Samsara, Sanofi, Sotio, Vascage, and Vasculox/Tioma. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Samsara Therapeutics, and Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis, and metabolic disorders.
